57 related articles for article (PubMed ID: 37417899)
1. Remarkable response to pazopanib plus vivolumab in a patient with pericardial synovial sarcoma carrying a novel genotype BRCA2 c.968dupT: A case report.
Zhang X; Xu Q; Zhang Y
Thorac Cancer; 2024 Mar; 15(8):667-671. PubMed ID: 38323364
[TBL] [Abstract][Full Text] [Related]
2. Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer.
Stanzione B; Del Conte A; Bertoli E; De Carlo E; Revelant A; Spina M; Bearz A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511255
[TBL] [Abstract][Full Text] [Related]
3. Addendum: Systemic AL amyloidosis: current approach and future direction.
Bou Zerdan M; Nasr L; Khalid F; Allam S; Bouferraa Y; Batool S; Tayyeb M; Adroja S; Mammadii M; Anwer F; Raza S; Chaulagain CP
Oncotarget; 2023 Jul; 14():721. PubMed ID: 37477528
[No Abstract] [Full Text] [Related]
4. Multiclonality of ER expression in DCIS - Implications for clinical practice and future research.
Thorat MA
Oncotarget; 2023 Jul; 14():719-720. PubMed ID: 37477525
[No Abstract] [Full Text] [Related]
5. The uncharacterized transcript
Yamakawa T; Zhang G; Najjar LB; Li C; Itakura K
Oncotarget; 2023 Jul; 14():723-737. PubMed ID: 37477523
[TBL] [Abstract][Full Text] [Related]
6. Development of a multiplex assay to assess activated p300/CBP in circulating prostate tumor cells.
Filon M; Yang B; Purohit TA; Schehr J; Singh A; Bigarella M; Lewis P; Denu J; Lang J; Jarrard DF
Oncotarget; 2023 Jul; 14():738-746. PubMed ID: 37477521
[TBL] [Abstract][Full Text] [Related]
7. Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.
Zhou J; Sturtevant D; Love C; Kulkarni A; Biyani N; Kathad U; Thacker E; Dave S; Bhatia K
Oncotarget; 2023 Jul; 14():722. PubMed ID: 37477520
[No Abstract] [Full Text] [Related]
8. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.
Sharma A; Shah SR; Illum H; Dowell J
Drugs; 2012 Dec; 72(17):2207-22. PubMed ID: 23116250
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
10. Intrathoracic synovial sarcoma with BRAF V600E mutation.
Russo I; Barresi S; Di Paolo PL; Di Ruscio V; Del Baldo G; Serra A; Vallese S; Miele E; Mastronuzzi A; Alaggio R; Ferrari A; Milano GM
Oncotarget; 2023 Jul; 14():703-708. PubMed ID: 37417899
[TBL] [Abstract][Full Text] [Related]
11. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
12. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
13. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
[TBL] [Abstract][Full Text] [Related]
14. Combination Treatment with the BRAF
Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
[TBL] [Abstract][Full Text] [Related]
15. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
